Heska Corp (HSKA) Receives Consensus Rating of “Hold” from Analysts

Heska Corp (NASDAQ:HSKA) has earned an average recommendation of “Hold” from the eight ratings firms that are currently covering the stock, Marketbeat reports. Two equities research analysts have rated the stock with a sell recommendation, two have assigned a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price among analysts that have updated their coverage on the stock in the last year is $109.33.

Several brokerages have weighed in on HSKA. BidaskClub downgraded Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Zacks Investment Research downgraded Heska from a “hold” rating to a “sell” rating in a report on Wednesday, January 3rd. Aegis reiterated a “buy” rating on shares of Heska in a report on Tuesday, December 19th. Raymond James Financial reiterated a “buy” rating on shares of Heska in a report on Monday, December 4th. Finally, B. Riley cut their price target on Heska from $96.50 to $93.00 and set a “neutral” rating for the company in a report on Friday, November 3rd.

In other news, insider Michael J. Mcginley sold 7,826 shares of the company’s stock in a transaction on Wednesday, November 29th. The stock was sold at an average price of $87.14, for a total transaction of $681,957.64. Following the completion of the sale, the insider now directly owns 106,771 shares in the company, valued at approximately $9,304,024.94. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Corporate insiders own 14.70% of the company’s stock.

Several hedge funds have recently added to or reduced their stakes in the company. Rhumbline Advisers increased its holdings in Heska by 8.6% in the 2nd quarter. Rhumbline Advisers now owns 12,554 shares of the medical research company’s stock valued at $1,281,000 after purchasing an additional 999 shares in the last quarter. Legal & General Group Plc increased its holdings in Heska by 13.5% in the 2nd quarter. Legal & General Group Plc now owns 11,666 shares of the medical research company’s stock valued at $1,190,000 after purchasing an additional 1,386 shares in the last quarter. Comerica Bank acquired a new stake in Heska in the 2nd quarter valued at $691,000. BNP Paribas Arbitrage SA increased its holdings in Heska by 59.2% in the 2nd quarter. BNP Paribas Arbitrage SA now owns 1,858 shares of the medical research company’s stock valued at $190,000 after purchasing an additional 691 shares in the last quarter. Finally, Victory Capital Management Inc. increased its holdings in Heska by 17.5% in the 2nd quarter. Victory Capital Management Inc. now owns 1,133 shares of the medical research company’s stock valued at $116,000 after purchasing an additional 169 shares in the last quarter. Institutional investors and hedge funds own 80.89% of the company’s stock.

Shares of Heska (NASDAQ:HSKA) traded down $0.24 on Friday, reaching $79.80. The company’s stock had a trading volume of 46,683 shares, compared to its average volume of 78,688. The firm has a market cap of $574.91, a P/E ratio of 42.00, a PEG ratio of 2.11 and a beta of 0.74. Heska has a 52 week low of $75.21 and a 52 week high of $115.00.

Heska (NASDAQ:HSKA) last issued its quarterly earnings results on Thursday, November 2nd. The medical research company reported $0.40 earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of $0.37 by $0.03. The company had revenue of $31.40 million during the quarter, compared to the consensus estimate of $36.10 million. Heska had a return on equity of 15.35% and a net margin of 10.67%. Heska’s revenue was down 6.0% on a year-over-year basis. During the same period in the previous year, the firm posted $0.45 EPS. analysts expect that Heska will post 2.03 EPS for the current year.

ILLEGAL ACTIVITY WARNING: “Heska Corp (HSKA) Receives Consensus Rating of “Hold” from Analysts” was first published by Ticker Report and is the property of of Ticker Report. If you are accessing this story on another website, it was illegally copied and reposted in violation of United States and international copyright law. The original version of this story can be viewed at https://www.tickerreport.com/banking-finance/3147758/heska-corp-hska-receives-consensus-rating-of-hold-from-analysts.html.

About Heska

Heska Corporation sells veterinary diagnostic and specialty products. The Company operates through two segments: Core Companion Animal Health (CCA) and Other Vaccines, Pharmaceuticals and Products (OVP). The CCA segment includes, primarily for canine and feline use, blood testing instruments and supplies, digital imaging products, software and services, local and cloud-based data services, allergy testing and immunotherapy, and single use offerings, such as in-clinic diagnostic tests and heartworm preventive products.

Analyst Recommendations for Heska (NASDAQ:HSKA)

Receive News & Ratings for Heska Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Heska and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

How to Trade on Forex – 8 Steps for Beginners
How to Trade on Forex – 8 Steps for Beginners
Super Nintendo World Theme Park Officially Starts Construction
Super Nintendo World Theme Park Officially Starts Construction
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Amazon and Apple Join Foxconn to Secure Chip Business of Toshiba
Camera Zooms In and Can Recognize Faces
Camera Zooms In and Can Recognize Faces
Netflix Could See 150 Million Worldwide Subscribers
Netflix Could See 150 Million Worldwide Subscribers
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back
LeEco Cutting Over 70% of Staff in U.S. Amidst Pull Back


© 2006-2018 Ticker Report. Google+.